SPECIAL REPORT
Improving Survival Rates in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Molecular Subtypes of Acute Myeloid Leukemia and the Prevalence of FLT3 Mutation Clinical Guidelines and Standards of Care for the Treatment of AML Urgent Need for More Targeted Agents for Relapsed and Refractory AML Patients The Evolving Role and Development of New Targeted Therapies
Published by Global Business Media